Literature DB >> 17939305

Tumorigenic epithelial stem cells and their normal counterparts.

V S Donnenberg1, J D Luketich, R J Landreneau, J A DeLoia, P Basse, A D Donnenberg.   

Abstract

ABC transporters are highly conserved and represent a major protective mechanism for barrier tissues as well as adult tissue stem cells. Emerging data support the existence of a cancer stem cell that shares features of tissue stem cells, including the ability to self-renew and undergo dysregulated differentiation. Here we show that a rare population of cells coexpressing MDR transporters and stem cell markers is a common feature across therapy-naive epithelial cancers as well as normal epithelial tissue. MDR+ and MDR- candidate tumor stem and progenitor populations were all capable of generating highly anaplastic transplantable human tumors in NOD/SCID. The finding that rare cells bearing stem cell markers and having intrinsic MDR expression and activity are already present within the tumorigenic compartment before treatment with cytotoxic agents is of critical importance to cancer therapy. Just as damaged normal epithelial tissues regenerate after chemotherapy by virtue of highly protected resting tissue stem cells, the existence of malignant counterparts in therapy-naive epithelial cancers suggests a common mechanism by which normal and tumor stem cells protect themselves against toxic injury.

Entities:  

Mesh:

Year:  2006        PMID: 17939305     DOI: 10.1007/2789_2007_054

Source DB:  PubMed          Journal:  Ernst Schering Found Symp Proc


  15 in total

1.  Localization of CD44 and CD90 positive cells to the invasive front of breast tumors.

Authors:  Vera S Donnenberg; Albert D Donnenberg; Ludovic Zimmerlin; Rodney J Landreneau; Rohit Bhargava; Ryan A Wetzel; Per Basse; Adam M Brufsky
Journal:  Cytometry B Clin Cytom       Date:  2010-04-30       Impact factor: 3.058

Review 2.  Regenerative therapy after cancer: what are the risks?

Authors:  Vera S Donnenberg; Ludovic Zimmerlin; Joseph Peter Rubin; Albert D Donnenberg
Journal:  Tissue Eng Part B Rev       Date:  2010-11-02       Impact factor: 6.389

3.  Arsenic-specific stem cell selection during malignant transformation.

Authors:  Erik J Tokar; Wei Qu; Jie Liu; Wei Liu; Mukta M Webber; James M Phang; Michael P Waalkes
Journal:  J Natl Cancer Inst       Date:  2010-03-25       Impact factor: 13.506

4.  Regenerative therapy and cancer: in vitro and in vivo studies of the interaction between adipose-derived stem cells and breast cancer cells from clinical isolates.

Authors:  Ludovic Zimmerlin; Albert D Donnenberg; J Peter Rubin; Per Basse; Rodney J Landreneau; Vera S Donnenberg
Journal:  Tissue Eng Part A       Date:  2010-09-17       Impact factor: 3.845

5.  The Mesenchymal State Predicts Poor Disease-Free Survival in Resectable Non-Small Cell Lung Cancer.

Authors:  Kunal Mehta; Erika Moravcikova; David McFall; James D Luketich; Arjun Pennathur; Albert D Donnenberg; Vera S Donnenberg
Journal:  Ann Thorac Surg       Date:  2017-05-09       Impact factor: 4.330

Review 6.  Mesenchymal stem cell secretome and regenerative therapy after cancer.

Authors:  Ludovic Zimmerlin; Tea Soon Park; Elias T Zambidis; Vera S Donnenberg; Albert D Donnenberg
Journal:  Biochimie       Date:  2013-06-05       Impact factor: 4.079

Review 7.  Stem cell sources and therapeutic approaches for central nervous system and neural retinal disorders.

Authors:  Diana Yu; Gabriel A Silva
Journal:  Neurosurg Focus       Date:  2008       Impact factor: 4.047

8.  Measurement of multiple drug resistance transporter activity in putative cancer stem/progenitor cells.

Authors:  Vera S Donnenberg; E Michael Meyer; Albert D Donnenberg
Journal:  Methods Mol Biol       Date:  2009

9.  Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents.

Authors:  Vera S Donnenberg; Rodney J Landreneau; Albert D Donnenberg
Journal:  J Control Release       Date:  2007-05-13       Impact factor: 9.776

10.  Persistence of side population cells with high drug efflux capacity in pancreatic cancer.

Authors:  Jing Zhou; Chun-You Wang; Tao Liu; Bin Wu; Feng Zhou; Jiong-Xin Xiong; He-Shui Wu; Jing Tao; Gang Zhao; Ming Yang; Shan-Miao Gou
Journal:  World J Gastroenterol       Date:  2008-02-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.